August 05, 2013
1 min read
Save

Study: Insulin bolus advisor improved glycemic control, patient satisfaction

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The first results from a 26-week trial indicate patients who used automated bolus advisors displayed improved glycemic control and treatment satisfaction without an increase for severe hypoglycemia.

“Our findings demonstrate that use of an automated bolus advisor can be efficacious and clinically meaningful in multiple daily insulin injection (MDI) therapy, and that most patients are willing and able to use this technology appropriately when adequate clinical support is provided,” Ralph Ziegler, MD, from the Diabetes Clinic for Children and Adolescents in Muenster, Germany, and colleagues wrote.

The Automated Bolus Advisor Control and Usability Study (ABACUS) examined the effects of using an insulin bolus advisor in a blood glucose meter on glycemic control and treatment satisfaction among 193 patients (mean age, 42.4 years) from 30 clinics in the United Kingdom and Germany with MDI and an HbA1c of 8.9% at baseline.

Ralph Ziegler, MD 

Ralph Ziegler

The patients were randomly assigned to an intervention group using Accu-Chek Aviva Expert (Roche) meter with an integrated bolus advisor (n=100), or control group that used a standard blood glucose meter and manual bolus calculator (n=93). Satisfaction was measured using the Diabetes Treatment Satisfaction Questionnaire scale.

According to data, the intervention group demonstrated a significant reduction in HbA1c (>0.5%) compared with the control group (56% vs. 34.4%; P<.01). Furthermore, the intervention group reported greater satisfaction compared with the control group (11.4 vs. 9; P<.01), researchers wrote.

“Overall, the percentage of blood glucose values <50 mg/dL remained at <2% in both groups throughout the study,” researchers wrote.

Disclosure: Ziegler received consulting fees for their involvement in the study. Other researchers report financial ties with Roche Diagnostics or Dexcom, Inc.